Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

While traditional 3D printers work by depositing layers of material, tomographic volumetric additive manufacturing (TVAM) ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Biogen stock took a hit Wednesday after the biotech company issued light guidance for 2025 despite beating most fourth-quarter expectations.

Biogen shares fell, after the biotechnology company forecast lower-than-expected revenue and profit for this year, saying multiple-sclerosis drug sales will decline further and will only be partially ...

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

It caps off the first full quarter with David Joyner, a longtime CVS executive, as CEO of the troubled retail drugstore chain ...

It’s critical to understand what a digitally savvy HCP is in 2025 and what’s impeding pharma's communications with this ...

Talkiatry, a leading provider of high-quality, in-network psychiatric care, today announced that it has been named to the 2025 New York Digital Health 100 (DH100), a recognition that highlights the ...